Trial Profile

Open-Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tapinarof (Primary)
Indications Plaque psoriasis
Focus Adverse reactions; Pharmacokinetics
Sponsors Dermavant Sciences

Most Recent Events

13 Oct 2022 According Dermavant Sciences media release, data from this study will be presented at the 2022 Fall Clinical Dermatology Conference.
28 Oct 2021 Results published in the American Journal of Clinical Dermatology.
23 Jun 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com